Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Status:
Unknown status
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety
of Lamazym for the treatment of patients with alpha-mannosidosis.